Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.94 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | UBE2N | P61088 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11575914 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL10771853 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL276602 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL20495958 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL20495969 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL20495963 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL20495967 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL20495961 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL20820762 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA | |
| SCHEMBL37403 | 1.00 | OPRM1 (0.94) | OPRM1TP53SPHK1CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| EP-2069320-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | Teva Pharmaceutical Industries Ltd. (IL) | 2009-06-17 | — | — | EP | claimed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | claimed |
| CN-119020446-A | Process for preparing chiral aryl amines, heteroaryl amines and alkyl amines | 河北工业大学 | 2024-11-26 | — | — | CN | disclosed |
| US-11581216-B2 | Semiconductor device structure with multiple liners and method for forming the same | NANYA TECHNOLOGY CORPORATION (TW) | 2023-02-14 | — | — | US | disclosed |
| US-10626511-B2 | Nanoelectrodes for water splitting | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-04-21 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| EP-2069320-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | Teva Pharmaceutical Industries Ltd. (IL) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | disclosed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | disclosed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | disclosed |
| EP-1836161-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | OPRM1 621/4885TP53 3935/4885SPHK1 3070/4885 |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | OPRM1 3621/4885TP53 1511/4885SPHK1 3217/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | OPRM1 4221/4885TP53 1545/4885SPHK1 2237/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | OPRM1 4180/4885TP53 2048/4885SPHK1 2122/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | OPRM1 384/4885TP53 3636/4885SPHK1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.